Marc Anthony Armand

Array ( [id] => 18140738 [patent_doc_number] => 20230014578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => GRANULES AND PREPARATION USING SAME [patent_app_type] => utility [patent_app_number] => 17/942333 [patent_app_country] => US [patent_app_date] => 2022-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17942333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18326266 [patent_doc_number] => 20230124394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => PI4KIIIBETA INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/941838 [patent_app_country] => US [patent_app_date] => 2022-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17941838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18182301 [patent_doc_number] => 20230043030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/823889 [patent_app_country] => US [patent_app_date] => 2022-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17823889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129133 [patent_doc_number] => 12371435 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors [patent_app_type] => utility [patent_app_number] => 17/822667 [patent_app_country] => US [patent_app_date] => 2022-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52848 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17822667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142946 [patent_doc_number] => 20230016791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => INHALABLE DRY POWDER AND AEROSOL FORMULATIONS OF JAK INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/821851 [patent_app_country] => US [patent_app_date] => 2022-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821851 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575444 [patent_doc_number] => 11731956 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors [patent_app_type] => utility [patent_app_number] => 17/891817 [patent_app_country] => US [patent_app_date] => 2022-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86879 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17891817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19151175 [patent_doc_number] => 11976071 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-07 [patent_title] => Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases [patent_app_type] => utility [patent_app_number] => 17/820770 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65141 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19564731 [patent_doc_number] => 12139492 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Substituted pyrimidines for the targeted degradation of Bruton's tyrosine kinase [patent_app_type] => utility [patent_app_number] => 17/820312 [patent_app_country] => US [patent_app_date] => 2022-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 43 [patent_no_of_words] => 36520 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17820312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667485 [patent_doc_number] => 12180213 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Substituted pyrazoles showing serotonin 5-HT receptor activity [patent_app_type] => utility [patent_app_number] => 17/889775 [patent_app_country] => US [patent_app_date] => 2022-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 45527 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 702 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17889775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18287744 [patent_doc_number] => 20230103216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA [patent_app_type] => utility [patent_app_number] => 17/886403 [patent_app_country] => US [patent_app_date] => 2022-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17886403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995883 [patent_doc_number] => 11912710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers [patent_app_type] => utility [patent_app_number] => 18/019047 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 41863 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18264895 [patent_doc_number] => 20230086137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-23 [patent_title] => CRYSTALLINE FORMS OF AN IRREVERSIBLE INHIBITOR OF MENIN-MLL INTERACTION [patent_app_type] => utility [patent_app_number] => 17/885213 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17885213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060126 [patent_doc_number] => 11939334 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-26 [patent_title] => Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers [patent_app_type] => utility [patent_app_number] => 18/019034 [patent_app_country] => US [patent_app_date] => 2022-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 55136 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 357 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18228361 [patent_doc_number] => 20230067355 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-one Derivatives Useful As Factor XIa Inhibitors [patent_app_type] => utility [patent_app_number] => 17/870142 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17870142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18065491 [patent_doc_number] => 20220396578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => QUINOXALINE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 17/866670 [patent_app_country] => US [patent_app_date] => 2022-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 412 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17866670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18319663 [patent_doc_number] => 20230117791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => SUBSTITUTED 1,2,3,4,5,6-HEXAHYDROAZEPINO[4,5-b]INDOLES FOR TREATING BRAIN DISORDERS [patent_app_type] => utility [patent_app_number] => 17/862646 [patent_app_country] => US [patent_app_date] => 2022-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17862646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18064492 [patent_doc_number] => 20220395579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE [patent_app_type] => utility [patent_app_number] => 17/849688 [patent_app_country] => US [patent_app_date] => 2022-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 107108 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -82 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17849688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945699 [patent_doc_number] => 20220332716 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS [patent_app_type] => utility [patent_app_number] => 17/808836 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20057 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19763180 [patent_doc_number] => 12221453 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-11 [patent_title] => Substituted pyrazolo[5',1':2,3]pyrimido[5,4-b][1,4]oxazines as TYK2 inhibitors [patent_app_type] => utility [patent_app_number] => 17/806893 [patent_app_country] => US [patent_app_date] => 2022-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100799 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 358 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17806893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18297977 [patent_doc_number] => 20230107663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/834135 [patent_app_country] => US [patent_app_date] => 2022-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17834135 [rel_patent_id] =>[rel_patent_doc_number] =>)